Genetically Engineered Mosquitoes: A Vector Control Technology for Reducing Virus Transmission [Updated September 8, 2020]   [open pdf - 431KB]

From the Document: "No vaccine exists for Zika, although the U.S. Food and Drug Administration (FDA) has approved several diagnostic tests for detecting Zika virus antibodies. Mosquito control and bite prevention are the first lines of defense. Conventional control methods such as truck and aerial spraying are only moderately effective (30%-50%) in reducing mosquito populations, in part owing to the resistance the mosquitoes have developed to common insecticides and to the limited area in which 'Aedes aegypti' mosquitoes circulate (100-200 yards from where the larvae emerge). 'Aedes aegypti' mosquitoes also tend to favor house interiors where spraying/fogging is not practical. Strategic placement of several low-cost autocidal gravid ovitraps (which mimic breeding sites) in house interiors can reduce the 'Aedes aegypti' population by about 50%. In this environment, the creation of a genetically engineered (GE) Aedes aegypti mosquito by the British firm Oxitec in 2002, known as OX513A, generated significant interest among public health officials. Developed originally to suppress the incidence of dengue fever, OX513A was seen as a promising technology to reduce the incidence of Zika virus transmission by reducing the population of mosquitoes. Oxitec is owned by Maryland-based Intrexon Corporation."

Report Number:
CRS In Focus, IF10401
Public Domain
Retrieved From:
Congressional Research Service: https://crsreports.congress.gov/
Media Type:
Help with citations